title: A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
abstract: BACKGROUND
  Irritable bowel syndrome is a common gastrointestinal disorder characterized by abdominal pain and discomfort and altered bowel habit. Antagonism at the 5-HT3 receptor may be of benefit in the treatment of irritable bowel syndrome.
  
  
  OBJECTIVE
  To evaluate the effect of 12 weeks of treatment with alosetron, a 5-HT3 receptor antagonist at doses of 0.1 mg b.d., 0.5 mg b.d. and 2 mg b.d. in irritable bowel syndrome patients.
  
  
  METHODS
  A double-blind, placebo-controlled, parallel-group study with a 2-week screening and a 12-week treatment period was conducted. A total of 462 patients (335 female) recorded details of the severity of their abdominal pain, and bowel function daily on a diary card throughout the study. At monthly clinic visits patients recorded the severity of their abdominal pain/discomfort and diarrhoea on a visual analogue scale.
  
  
  RESULTS
  In the total population and in the female subpopulation (but not in males) alosetron 2 mg b.d. significantly increased the proportion of pain-free days and decreased the visual analogue scale score for diarrhoea compared with placebo. Alosetron at doses of 0.5 mg b.d. and 2 mg b.d. led to a significant hardening of stool, and a reduction in stool frequency in the total population.
  
  
  CONCLUSIONS
  Alosetron at a dose of 2 mg b.d. is an effective treatment for female patients with irritable bowel syndrome.
authors.affiliation: Rotherham General Hospital, UK.
authors.forename: K D
authors.initials: KD
authors.lastname: Bardhan
authors.forename: G
authors.initials: G
authors.lastname: Bodemar
authors.forename: H
authors.initials: H
authors.lastname: Geldof
authors.forename: E
authors.initials: E
authors.lastname: Schütz
authors.forename: A
authors.initials: A
authors.lastname: Heath
authors.forename: J G
authors.initials: JG
authors.lastname: Mills
authors.forename: L A
authors.initials: LA
authors.lastname: Jacques
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002243:Carbolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010147:Pain Measurement; D011985:Receptors, Serotonin / Q000187:drug effects*; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012727:Sex Characteristics; D013997:Time Factors
chemical_list: D002243:Carbolines; D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists; C090840:alosetron